Immunocheckpoint Blockade in Malignant Pleural Mesothelioma by Fujimoto, Nobukazu
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Immunocheckpoint Blockade in 
Malignant Pleural Mesothelioma
Nobukazu Fujimoto
Abstract
Targeting immunocheckpoint with immunomodulatory monoclonal antibodies 
has proven to be an effective antitumor strategy across a variety of cancers. The 
immunosuppressive tumor microenvironment in malignant pleural mesothelioma 
(MPM) has suggested that MPM might benefit from this kind of immunotherapy. 
In recent years, immunocheckpoint inhibitors (ICIs) have shown encouraging 
results for patients with MPM. Antibodies against programmed death 1 (PD-1) 
and PD-ligand 1 (PD-L1) have demonstrated favorable response, progression-free 
survival, and overall survival. The toxicity profiles were similar to those observed 
with ICIs in other malignancies, like melanoma and non-small cell lung cancer, and 
they appeared to be manageable. Nivolumab, an anti-PD-1 antibody, was approved 
in Japan for advanced or metastatic MPM patients resistant or intolerant to other 
chemotherapies. Important future issues include developing a combination therapy, 
where ICIs are combined with other agents (including other ICIs), and developing 
biomarkers for determining which patients might respond well and which might 
experience unacceptable toxicities.
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1. Introduction
Malignant pleural mesothelioma (MPM) is a rare pleural malignancy that is 
associated with asbestos exposure. Gemba et al. reported that more than 70% 
of malignant mesothelioma cases in Japan were associated with occupational or 
environmental asbestos exposure [1]. MPM is a highly aggressive neoplasm with a 
poor prognosis; the median overall survival (OS) is only about 12 months. Systemic 
chemotherapy with platinum plus pemetrexed is the recommended first-line 
systemic therapy for advanced MPM [2]. Some clinical trials have examined the 
efficacy of new agents to improve the results of the platinum/pemetrexed combina-
tion; however, no new agent has demonstrated significant clinical efficacy. Thus, 
the pemetrexed/platinum combination remains the standard treatment.
Currently, there is no recommended treatment option for MPM after first-
line platinum/pemetrexed chemotherapy. Re-treatment with pemetrexed-based 
chemotherapy is a reasonable option for patients that achieved durable disease 
control with the first-line chemotherapy [3]. Other treatment options of salvage 
chemotherapy include vinorelbine and gemcitabine; however, the median OS with 
these agents only ranges from 5 to 10 months [4, 5]. Other experimental agents, 
such as angiogenesis inhibitors [6] or tyrosine kinase inhibitors [7], have not 
demonstrated efficacy.
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Targeting immunocheckpoint with immunomodulatory monoclonal antibodies 
was shown to be an effective antitumor strategy across a variety of cancers [8]. The 
immunosuppressive tumor microenvironment in MPM has suggested that MPM 
might benefit from this kind of immunotherapy [9, 10]. In fact, in recent years, 
immunocheckpoint inhibitors (ICIs) have shown some encouraging results for 
patients with MPM.
In this chapter, we review recent clinical findings on several ICIs, including 
anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody, anti-
programmed death 1 (PD-1) antibody, and anti-PD-ligand 1 (PD-L1) antibody, for 
treating patients with MPM.
2. Anti-CTLA-4 antibody
Anti-CTLA-4 antibody was the first ICI described for treating MPM. Phase II stud-
ies demonstrated that tremelimumab, a selective human monoclonal antibody against 
CTLA-4, showed favorable activity as a second-line treatment for MPM [11, 12]. 
However, a double-blind study that compared tremelimumab to placebo in subjects 
with previously treated, unresectable malignant mesothelioma (DETERMINE study) 
failed to demonstrate differences in OS or progression-free survival (PFS) between the 
treatment and placebo groups [13]. After that, anti-CTLA-4 antibodies were studied in 
combination with an anti-PD-1 or anti-PD-L1 antibody.
3. Anti-PD-L1 antibody
Avelumab is a human IgG1 monoclonal antibody that targets PD-L1 [14]. A 
phase 1b open-label study (JAVELIN solid tumor) was conducted in patients with 
unresectable mesothelioma that progressed after platinum/pemetrexed treatment; 
patients were enrolled at 25 sites in three countries [15]. Of 53 patients treated, 
the objective response rate (RR) was 9% (95% confidence interval [95%CI]: 
3.1–20.7%); one patient experienced a complete response, and four patients 
experienced a partial response. Responses were durable (median, 15.2 months; 
95%CI: 11.1 to non-estimable) and occurred in patients with PD-L1-positive 
tumors (RR: 19%; 95%CI: 4.0–45.6) and PD-L1-negative tumors (RR: 7%; 95%CI: 
0.9–24.3), based on a 5% or greater cutoff for PD-L1 expression. The median PFS 
was 4.1 months (95%CI: 1.4–6.2), and the 12-month PFS rate was 17.4% (95%CI: 
7.7–30.4). The median OS was 10.7 months (95%CI: 6.4–20.2).
4. Anti-PD-1 antibody
4.1 Pembrolizumab
A nonrandomized, phase Ib trial was conducted to test pembrolizumab in 
patients with PD-1-positive MPM that had been treated previously. In the prelimi-
nary report, 20% of patients experienced an objective response, 72% experienced 
disease control, and the median OS was 18 months (95%CI: 9.4 to non-estimable) 
[16]. Then, a phase II trial assessed pembrolizumab activity in 65 unselected 
patients with MPM [17]. The objective RR was 19% and the disease control rate was 
66%. The median PFS was 4.5 months (95%CI: 2.3–6.2), and the median OS was 
11.5 months (95%CI: 7.6–14).
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After those promising results, pembrolizumab was used off-label in Switzerland 
and Australia [18]. A total of 93 patients (48 from Switzerland and 45 from 
Australia) were treated. In those cohorts, the overall RR was 18%, the median PFS 
was 3.1 months, and the median OS was 7.2 months. Among patients with the non-
epithelioid histological subtype, pembrolizumab treatment improved the objective 
RR (24% vs. 16%; p = 0.54) and the median PFS (5.6 vs. 2.8 months; p = 0.02).
4.2 Nivolumab
Another anti-PD-1 antibody, nivolumab, was first tested in recurrent MPM in 
the Netherlands [19]. In that single-center trial, patients with MPM received 3 mg/
kg intravenous nivolumab every 2 weeks. Of the 34 patients included, eight patients 
(24%) displayed a partial response and another eight displayed stable disease, 
which resulted in a disease control rate of 47%. Japanese investigators also evaluated 
the efficacy and safety of nivolumab for advanced MPM in patients that were resis-
tant or intolerant to prior chemotherapy [20]. Thirty-four patients were enrolled, 
and 10 patients (29.4%, 95%CI: 16.8–46.2) showed an objective response in a central 
assessment. Objective RRs were 25.9, 66.7, and 25.0% for epithelioid, sarcomatous, 
and biphasic histological subtypes, respectively (Figure 1). The median OS and PFS 
were 17.3 and 6.1 months, respectively (Figure 2a and b). Based on these findings, 
Figure 1. 
A waterfall plot of the MERIT study results, which demonstrates the maximum percentage changes compared 
to baseline in target lesions of each patient, according to histological subtype (Ref. [20]).
Figure 2. 
Kaplan-Meier curves show survival for all patients and for patients grouped according to programmed death-
ligand 1 (PD-L1) expression in the MERIT study (Ref. [20]). (a) Overall survival (OS); (b) progression-free 
survival (PFS). HRs compare the PD-L1 ≥ 1% group to the <1% group. CI, confidence interval; HR, hazard 
ratio; NR, not reached.
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nivolumab was approved in Japan for patients with advanced or metastatic MPM 
that are resistant or intolerant to previous chemotherapy.
Although the effect requires confirmation in larger clinical trials, nivolumab and 
pembrolizumab might offer hope for patients with MPM.
5. Toxicity
The toxicity of these ICIs was acceptable in MPM. A study on pembrolizumab 
toxicity found grade 3 and 4 events, including adrenal insufficiency (3%), pneumonitis 
(3%), skin rash (3%), colitis (1.6%), confusion (1.6%), hepatitis (1.6%), and hypergly-
cemia (1.6%), and one grade 5 event of hepatitis (1.6%) [17]. In a study on nivolumab, 
adverse events of any grade occurred in 26 patients (76%), including fatigue (29%) 
and pruritus (15%) [19]. In that study, treatment-related grade 3 and 4 adverse events 
were reported in nine patients (26%); most events were pneumonitis, gastrointestinal 
disorders, and laboratory disorders. One treatment-related death was due to pneumo-
nitis, but it was probably initiated by concurrent amiodarone therapy. These toxicity 
profiles were similar to those observed in other malignancies, including melanoma and 
non-small cell lung cancer (NSCLC), and they appeared to be manageable.
6. Future perspectives
Based on the promising results described above, ICIs could play a primary role in 
the treatment of MPM. An important issue for the future is whether ICIs can be com-
bined with other agents, including other ICIs. For example, given the synergy between 
the PD-1/PD-L1 and CTLA-4 pathways in T-cell activation, a combination treatment 
with antibodies that target PD-1 or PD-L1 and CTLA-4 warrants investigation [22].
NIBIT-MESO-1 was an open-label, nonrandomized, phase II study that investi-
gated the efficacy and safety of first- or second-line tremelimumab, a monoclonal 
antibody against CTLA-4, combined with durvalumab, a monoclonal antibody 
against PD-L1 [23]. In that study, patients with unresectable pleural or peritoneal 
mesothelioma received one dose of intravenous tremelimumab and durvalumab 
delivered every 4 weeks, for a total of four doses. This was followed by maintenance 
treatment with intravenous durvalumab. Of 40 patients, 11 (28%) displayed an 
objective response. The median PFS was 5.7 months (95%CI: 1.7–9.7), and the 
median OS was 16.6 months (95%CI: 13.1–20.1). Toxicity related to treatment was 
generally manageable and reversible.
Another multicenter, randomized, phase II study was conducted in France [24]. In 
that study, patients were randomly allocated to nivolumab or nivolumab plus ipilim-
umab. In the intention-to-treat population, the primary endpoint, 12-week disease 
control, was achieved by 25 (40%; 95%CI: 28–52) of 63 patients in the nivolumab group 
and by 32 (52%; 95%CI: 39–64) of 62 patients in the combination group. The most 
frequent grade 3 adverse events were asthenia (N = one [2%] with nivolumab vs. three 
[5%] with the combination), an asymptomatic increase in aspartate aminotransferase 
or alanine aminotransferase (N = none with nivolumab vs. four [7%] of each with the 
combination), and an asymptomatic increase in lipase (N = two [3%] with nivolumab 
vs. one [2%] with the combination). These findings indicated that the combination 
of anti-CTLA-4 and anti-PD1/PD-L1 antibodies appeared to be active and had a good 
safety profile in patients with MPM. Currently, there is an ongoing phase III, random-
ized, open-label trial for testing nivolumab in combination with ipilimumab vs. peme-
trexed with cisplatin or carboplatin as a first-line therapy in unresectable MPM. The 
primary endpoint of the study, OS, will be reported in the near future.
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The combination of an anti-PD-1/PD-L1 antibody and conventional chemo-
therapy is also under investigation. Nowak et al. presented results from a phase II 
trial that tested durvalumab combined with cisplatin/pemetrexed in MPM [25]. 
The primary endpoint, PFS at 6 months, was 57% (N = 31/54; 95%CI: 45–68), 
the median PFS time was 6.9 months (95%CI: 5.5–9.0), and the objective RR was 
48% (95%CI: 35–61). Grade 3–5 adverse events occurred in 36 patients, including 
neutropenia in 13%, nausea in 11%, anemia in 7%, fatigue in 6%, and any grade of 
peripheral neuropathy in 35%. The authors have conducted another phase II study 
to test the combination of nivolumab and cisplatin/pemetrexed, which is currently 
in progress (Figure 3)[21]. A large-scale randomized study for testing the combi-
nation of pembrolizumab and cisplatin/pemetrexed is also in progress. Based on 
whether these combination regimens, which include anti-PD1/PD-L1 antibodies, 
demonstrate sufficient activity, safety, and tolerability as first-line treatments, the 
standard regimen of cisplatin/pemetrexed might be replaced.
Another important issue is whether biomarkers can be developed to determine 
which patients might expect a response and which might expect unacceptable tox-
icity. Previous studies in patients with MPM have shown that tumors with positive 
PD-L1 expression were associated with worse survival outcomes compared to 
those with negative PD-L1 expression [26]. Although an optimal PD-L1 expres-
sion threshold could not be identified, a trend was observed, where a higher 
RR and more durable PFS were associated with increasing PD-L1 expression, in 
studies on pembrolizumab [17, 18] and nivolumab [20]. In some neoplasms, the 
tumor mutation burden or the tumor microenvironment was associated with the 
response to ICIs; however, those associations have not been established as bio-
markers in MPM.
7. Conclusion
The prognosis of MPM remains poor. Recent encouraging results have sug-
gested that a PD-1/PD-L1 blockade might be an effective treatment option 
Figure 3. 
Overview of a phase II trial for testing a first-line combination chemotherapy with cisplatin/pemetrexed and 
nivolumab for treating unresectable malignant pleural mesothelioma (Ref. [21]). RECIST, response evaluation 
criteria in solid tumors; ECOG, eastern cooperative oncology group; PS, performance status.
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for MPM. Although the effect requires confirmation in larger clinical trials, 
nivolumab and pembrolizumab might offer hope for patients with MPM. Further 
study is warranted to develop more effective treatment strategies, such as com-
bining ICI with other ICIs or with conventional chemotherapy, and to establish 
biomarkers for distinguishing patients that might respond to treatment from 
those likely to develop unacceptable toxicities.
Acknowledgements
This study was supported by grants-in-aid from the Ministry of Health, Labor, 
and Welfare, Japan.
Conflict of interest
The author received consultancy fees from Boehringer Ingelheim, Ono, 
Bristol-Myers Squibb, Kyorin, and Kissei, and honoraria or research funding from 
Hisamitsu, Chugai, Ono, Taiho, Boehringer Ingelheim, Bristol-Myers Squibb, 
Novartis, GlaxoSmithKline, and MSD.
Author details
Nobukazu Fujimoto
Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan
*Address all correspondence to: nobufujimot@gmail.com
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
7Immunocheckpoint Blockade in Malignant Pleural Mesothelioma
DOI: http://dx.doi.org/10.5772/intechopen.89116
References
[1] Gemba K, Fujimoto N, Kato K, 
Aoe K, Takeshima Y, Inai K, et al. 
National survey of malignant 
mesothelioma and asbestos 
exposure in Japan. Cancer Science. 
2012;103:483-490. DOI: 
10.1111/j.1349-7006.2011.02165.x
[2] Vogelzang NJ, Rusthoven JJ, 
Symanowski J, Denham C, Kaukel E, 
Ruffie P, et al. Phase III study of 
pemetrexed in combination with 
cisplatin versus cisplatin alone in 
patients with malignant pleural 
mesothelioma. Journal of Clinical 
Oncology. 2003;21:2636-2644. DOI: 
10.1200/JCO.2003.11.136
[3] Bearz A, Talamini R, Rossoni G, 
Santo A, de Pangher V, Fasola G, et al. 
Re-challenge with pemetrexed in 
advanced mesothelioma: A multi-
institutional experience. BMC 
Research Notes. 2012;5:482. DOI: 
10.1186/1756-0500-5-482
[4] Bibby AC, Tsim S, Kanellakis N, 
Ball H, Talbot DC, Blyth KG, et al. 
Malignant pleural mesothelioma: An 
update on investigation, diagnosis 
and treatment. European Respiratory 
Review. 2016;25:472-486. DOI: 
10.1183/16000617.0063-2016
[5] Buikhuisen WA, Hiddinga BI, Baas P, 
van Meerbeeck JP. Second line therapy 
in malignant pleural mesothelioma: 
A systematic review. Lung Cancer. 
2015;89:223-231. DOI: 10.1016/j.
lungcan.2015.06.018
[6] Buikhuisen WA, Burgers JA, 
Vincent AD, Korse CM, van Klaveren RJ, 
Schramel FM, et al. Thalidomide versus 
active supportive care for maintenance 
in patients with malignant mesothelioma 
after first-line chemotherapy (NVALT 5):  
An open-label, multicentre, randomised 
phase 3 study. The Lancet Oncology. 
2013;14:543-551. DOI: 10.1016/
S1470-2045(13)70125-6
[7] Mathy A, Baas P, Dalesio O, van 
Zandwijk N.Limited efficacy of imatinib 
mesylate in malignant mesothelioma: A 
phase II trial. Lung Cancer. 2005;50:83-86. 
DOI: 10.1016/j.lungcan.2005.04.010
[8] Wilson RAM, Evans TRJ, Fraser AR, 
Nibbs RJB. Immune checkpoint 
inhibitors: New strategies to checkmate 
cancer. Clinical and Experimental 
Immunology. 2018;191:133-148. DOI: 
10.1111/cei.13081
[9] Bograd AJ, Suzuki K, Vertes E, 
Colovos C, Morales EA, Sadelain M, 
et al. Immune responses and 
immunotherapeutic interventions 
in malignant pleural mesothelioma. 
Cancer Immunology, Immunotherapy. 
2011;60:1509-1527. DOI: 10.1007/
s00262-011-1103-6
[10] Hegmans JP, Hemmes A, 
Hammad H, Boon L, Hoogsteden HC, 
Lambrecht BN. Mesothelioma 
environment comprises cytokines 
and T-regulatory cells that 
suppress immune responses. 
The European Respiratory 
Journal. 2006;27:1086-1095. DOI: 
10.1183/09031936.06.00135305
[11] Calabro L, Morra A, Fonsatti E, 
Cutaia O, Amato G, Giannarelli D, 
et al. Tremelimumab for patients with 
chemotherapy-resistant advanced 
malignant mesothelioma: An open-
label, single-arm, phase 2 trial. The 
Lancet Oncology. 2013;14:1104-1111. 
DOI: 10.1016/S1470-2045(13)70381-4
[12] Calabro L, Morra A, Fonsatti E, 
Cutaia O, Fazio C, Annesi D, et al. 
Efficacy and safety of an intensified 
schedule of tremelimumab for 
chemotherapy-resistant malignant 
mesothelioma: An open-label, 
single-arm, phase 2 study. The Lancet 
Respiratory Medicine. 2015;3:301-309. 
DOI: 10.1016/S2213-2600(15)00092-2
Asbestos-Related Diseases
8
[13] Maio M, Scherpereel A, Calabro L, 
Aerts J, Cedres Perez S, Bearz A, et al. 
Tremelimumab as second-line or third-
line treatment in relapsed malignant 
mesothelioma (DETERMINE): A 
multicentre, international, randomised, 
double-blind, placebo-controlled 
phase 2b trial. The Lancet Oncology. 
2017;18:1261-1273. DOI: 10.1016/
S1470-2045(17)30446-1
[14] Heery CR, O’Sullivan-Coyne G, 
Madan RA, Cordes L, Rajan A, 
Rauckhorst M, et al. Avelumab for 
metastatic or locally advanced 
previously treated solid tumours 
(JAVELIN solid tumor): A phase 1a, 
multicohort, dose-escalation trial. The 
Lancet Oncology. 2017;18:587-598. DOI: 
10.1016/S1470-2045(17)30239-5
[15] Hassan R, Thomas A, Nemunaitis JJ, 
Patel MR, Bennouna J, Chen FL, et al. 
Efficacy and safety of avelumab 
treatment in patients with advanced 
unresectable mesothelioma: Phase 1b 
results from the JAVELIN solid tumor 
trial. JAMA Oncology. 2019;5:351-357. 
DOI: 10.1001/jamaoncol.2018.5428
[16] Alley EW, Lopez J, Santoro A, 
Morosky A, Saraf S, Piperdi B, et al. 
Clinical safety and activity of 
pembrolizumab in patients with 
malignant pleural mesothelioma 
(KEYNOTE-028): Preliminary results 
from a non-randomised, open-label, 
phase 1b trial. The Lancet Oncology. 
2017;18:623-630. DOI: 10.1016/
S1470-2045(17)30169-9
[17] Desai A, Karrison T, Rose B, Tan Y, 
Hill B, Pemberton E, et al. Phase II trial 
of pembrolizumab (NCT02399371) 
in previously-treated malignant 
mesothelioma: Final analysis. Journal of 
Thoracic Oncology. 2018;13:S339
[18] Metaxas Y, Rivalland G, Mauti LA, 
Klingbiel D, Kao S, Schmid S, et al. 
Pembrolizumab as palliative 
immunotherapy in malignant pleural 
mesothelioma. Journal of Thoracic 
Oncology. 2018;13:1784-1791. DOI: 
10.1016/j.jtho.2018.08.007
[19] Quispel-Janssen J, van der Noort V, 
de Vries JF, Zimmerman M, Lalezari F, 
Thunnissen E, et al. Programmed death 
1 blockade with nivolumab in patients 
with recurrent malignant pleural 
mesothelioma. Journal of Thoracic 
Oncology. 2018;13:1569-1576
[20] Okada M, Kijima T, Aoe K, Kato T, 
Fujimoto N, Nakagawa K, et al. Clinical 
efficacy and safety of nivolumab: 
Results of a multicenter, open-label, 
single-arm, Japanese phase 2 study 
in malignant pleural mesothelioma 
(MERIT). Clinical Cancer Research. 
2019. DOI: 10.1158/1078-0432.CCR- 
19-0103. pii: clincanres.0103.2019
[21] Fujimoto N, Aoe K, Kozuki T, 
Oze I, Kato K, Kishimoto T, et al. A 
phase II trial of first-line combination 
chemotherapy with cisplatin, 
pemetrexed, and nivolumab for 
unresectable malignant pleural 
mesothelioma: A study protocol.  
Clinical Lung Cancer. 2018;19:e705-e707. 
DOI: 10.1016/j.cllc.2018.05.001
[22] Das R, Verma R, Sznol M, 
Boddupalli CS, Gettinger SN, Kluger H, 
et al. Combination therapy with anti-
CTLA-4 and anti-PD-1 leads to distinct 
immunologic changes in vivo. Journal 
of Immunology. 2015;194:950-959. DOI: 
10.4049/jimmunol.1401686
[23] Calabro L, Morra A, Giannarelli D, 
Amato G, D’Incecco A, Covre A, et al. 
Tremelimumab combined with 
durvalumab in patients with 
mesothelioma (NIBIT-MESO-1): An 
open-label, non-randomised, phase 2 
study. The Lancet Respiratory Medicine. 
2018;6:451-460. DOI: 10.1016/
S2213-2600(18)30151-6
[24] Scherpereel A, Mazieres J, 
Greillier L, Lantuejoul S, Do P, 
Bylicki O, et al. French Cooperative 
Thoracic, Intergroup. Nivolumab or 
9Immunocheckpoint Blockade in Malignant Pleural Mesothelioma
DOI: http://dx.doi.org/10.5772/intechopen.89116
nivolumab plus ipilimumab in patients 
with relapsed malignant pleural 
mesothelioma (IFCT-1501 MAPS2): A 
multicentre, open-label, randomised, 
non-comparative, phase 2 trial. The 
Lancet Oncology. 2019;20:239-253.  
DOI: 10.1016/S1470-2045(18)30765-4
[25] Nowak AKP, Lesterhuis W, 
Hughes B, Brown C, Kao S, 
Karikios D, et al. DREAM—A phase 
2 trial of durvalumab with first line 
chemotherapy in mesothelioma: Final 
result. Journal of Thoracic Oncology. 
2018;13(10, Supplement):S338-S3S9
[26] Cedres S, Ponce-Aix S, 
Zugazagoitia J, Sansano I, Enguita A, 
Navarro-Mendivil A, et al. Analysis of 
expression of programmed cell death 1 
ligand 1 (PD-L1) in malignant pleural 
mesothelioma (MPM). PLoS One. 
2015;10:e0121071. DOI: 10.1371/journal.
pone.0121071
